In a generally lackluster big-cap med-tech market, Stryker (NYSE:SYK)
has stood out as a comparatively strong performer. Given the company's
broad-based business mix, as well as its willingness to deploy capital
into M&A to improve the business, I believe investors can reasonably
expect this company to continue to be a solid operational story within
the space. Stryker's positive qualities are seldom forgotten, though,
and while I wouldn't call the shares overvalued, I don't see them as
undervalued either.
Read more here:
Stryker Continues To Reap The Benefits Of A Strong Model
No comments:
Post a Comment